Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Non Hodgkin Lymphoma Intervention: Drug: Tenalisib, Sponsor: Rhizen Pharmaceuticals SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials